ipilimumab,nivolumab
bms
['crpc', 'nsclc', 'niche-2', 'sclc']
#esmo22 day 3 highlights: impressive results from niche-2 trial, superior clinical benefit in mcrpc and nsclc. 
Plan, consolidate data, and synthesize insights from life science conferences and social media with https://t.co/Fhm0QpaU5o, a product of @ZoomRx.